

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.

NAME Kathleen M. Egan	POSITION TITLE		
eRA COMMONS USER NAME EGANKM	Professor		
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
University of Connecticut, Storrs, CT	BS	1979	Biology
Boston University, Boston, MA	MPH	1984	Public Health
Harvard University, Cambridge, MA	ScD	1996	Epidemiology

A. POSITIONS AND HONORS

- 4/89-6/91 Research Associate, Department of Ophthalmology, Harvard Medical School
- 7/91-6/97 Instructor, Department of Ophthalmology, Harvard Medical School
- 7/96-6/98 Research Associate, Department of Epidemiology Harvard School of Public Health
- 7/97-5/02 Assistant Professor, Department of Ophthalmology Harvard Medical School
- 7/98-5/02 Assistant Professor, Department of Epidemiology Harvard School of Public Health
- 6/02-9/06 Associate Professor, Department of Medicine Vanderbilt University
- 1/03-6/06 Associate Professor (Adjunct), Department of Epidemiology Harvard School of Public Health
- 9/06- Professor, Departments of Oncologic Sciences & Department of Biostatistics& Epidemiology University of South Florida
- 9/06- Senior Member, Risk Detection, Prevention & Intervention Program Moffitt Cancer Center & Research Institute

OTHER PROFESSIONAL ACTIVITIES

Epidemiology peer review panel, Breast Cancer Research Program, USAMRDC, 1997-present
Epidemiology peer review panel (ad hoc), National Cancer Institute, 6/98-present

B. SELECED PUBLICATIONS (of more than 130)

1. Glynn R, Seddon J, Gragoudas E, **Egan KM**, Hart L. Evaluation of tumor regression and other prognostic factors for early and late metastasis after proton beam irradiation of uveal melanoma. *Ophthalmology* 1989; 96:1566-1573.
2. **Egan KM**, Gragoudas E, Seddon J, Glynn R, Munzenrider J, Goitein M, Verhey L, Urie M, Koehler A. The risk of enucleation after proton beam irradiation of uveal melanoma. *Ophthalmology* 1989; 96: 1377-83.
3. **Egan KM**, Gragoudas ES, Seddon JM, Walsh SM. Smoking and the risk of early metastases from choroidal melanoma. *Ophthalmology* 1992; 99:537-41.
4. **Egan KM**, Walsh SM, Seddon JM, Gragoudas ES. An evaluation of reproductive factors on the risk of metastases from uveal melanoma. *Ophthalmology* 1993; 100: 1160-66.
5. Giovannucci E, **Egan KM**, Hunter DJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in the Nurses' Health Study. *New Engl J Med* 1995; 333:609-14.

6. Wang X, **Egan KM**, Gragoudas ES, Kelsey KT. Constitutional alterations on chromosome 9 in patients with uveal melanoma. *Melanoma Research* 1996; 6: 405-10.
7. **Egan KM**, Stampfer M, Giovannucci E, Rosner B, Colditz GA. A prospective study of regular aspirin use and the risk of breast cancer. *J Natl Cancer Inst* 1996; 88:988-93.
8. **Egan KM**, Newcomb PM, Longnecker MP, Dietz AT, Baron JA, Trichopoulos D, Stampfer MJ, Willett WC. Jewish religion and risk of breast cancer. *Lancet* 1996; 347:1645-4.
9. **Egan KM**, Giovannucci E, Titus-Ernstoff L, Newcomb P, Stampfer M. Middle-aged mothers live longer [letter]. *Nature* 1997; 389: 922.
10. Lane AM, **Egan KM**, Yang J, Saornil MA, Alroy J, Albert D, Gragoudas ES. An evaluation of tumor vascularity as a prognostic indicator in uveal melanoma. *Melanoma Research* 1997; 7:237-242.
11. **Egan KM**, Ryan L, Gragoudas ES. Survival implications of enucleation after radiotherapy for choroidal melanoma: An example of regression on time-dependent covariates. *Arch Ophthalmol* 1998; 116: 366-370.
12. **Egan KM**, Stampfer MJ, Rosner BA, Trichopoulos D, Newcomb PA, Trentham-Dietz A, Longnecker MP, Mittendorf R, Greenberg ER, Willett WC. Risk factors for breast cancer in women with a family history of breast cancer. *Cancer Epi Bio Prev* 1998; 7: 359-364.
13. Serova-Sinilnikova O, **Egan KM**, Quinn JL, Boutrand L, Lenoir G, Stoppa-Lyonnet D, Desjardins L, Levy C, Goldgar D, and Gragoudas ES. Germline BRCA2 sequence variants in patients with ocular melanoma. *Int J Cancer* 1999; 82: 325-328.
14. Regan S, Judge H, Gragoudas ES, **Egan KM**. Iris color as a prognostic indicator in intraocular melanoma. *Arch Ophthalmol* 1999; 117: 811-814.
15. **Egan KM**, Quinn JL, Gragoudas ES. History of childbearing confers a survival advantage in choroidal melanoma. *Arch Ophthalmol* 1999; 117: 939-942.
16. Li W, Judge H, Gragoudas ES, Seddon JM, **Egan KM**. Patterns of tumor initiation in choroidal melanoma. *Cancer Research* 2000; 60:3757-3760.
17. Li W, Gragoudas ES, **Egan KM**. Metastatic melanoma death by anatomic site after proton beam irradiation for uveal melanoma. *Arch Ophthalmol* 2000; 118:1066-70.
18. **Egan KM**, Stampfer MJ, Hunter D, Hankinson S, Rosner BA, Holmes M, Willett WC, Colditz GA. Active and passive smoking in breast cancer: results from the Nurses' Health Study. *Epidemiology* 2002; 13:138-45.
19. Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, **Egan KM**. Evidence-based estimates of outcome in patients irradiated for intraocular melanoma. *Arch Ophthalmol*. 2002 Dec;120(12):1665-71.
20. **Egan KM**, Newcomb PA, Titus-Ernstoff L, Trentham-Dietz A, Mignone LI, Farin F, Hunter DJ. Association of *NAT2* and smoking in relation to breast cancer incidence in a population-based case-control study. *Cancer Causes & Control* 2003 14(1):43-51.
21. Fung TT, Spiegelman D, **Egan KM**, Giovannucci E, Hunter DJ, Willett WC. Vitamin and carotenoid intake and risk of squamous cell carcinoma of the skin. *Int J Cancer*. 2003 Jan 1; 103(1): 110-5.
22. Li W, Gragoudas ES, **Egan KM**. Tumor basal area and metastatic death after proton beam irradiation for choroidal melanoma. *Arch Ophthalmol*. 2003 Jan; 121(1): 68-72.
23. **Egan KM**, Thompson PA, Titus-Ernstoff L, Moore JH, Ambrosone CB. *MnSOD* polymorphism and breast cancer in a population-based case-control study. *Cancer Lett* 2003 Sep 10;199(1):27-33.
24. **Egan KM**, Cai Q, Shu X-O, Jin F, Zhu T-L, Dai Q, Gao Y-T, Zheng W. Genetic polymorphisms in *GSTM1*, *GSTP1* and *GSTT1* and the risk for breast cancer: Results from the Shanghai breast cancer study and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2004 13:197-204.
25. **Egan KM**, Newcomb PA, Ambrosone CB, Trentham-Dietz A, Titus-Ernstoff L, Hampton JM, Kimura M, Nagase H. *STK15* polymorphism and breast cancer risk in a population-based case-control study. *Carcinogenesis* 2004 25:2149-53.
26. **Egan KM**, Sosman J, Blot WJ. Sunlight and a reduced risk of cancer: is the real story vitamin D? [Editorial] *J Natl CA Inst* 2005; 97: 161-163.
27. Zhang Y, Newcomb PA, **Egan KM**, Titus-Ernstoff L, Chanock S, Welch R, Brinton L, Lissowska J, Szeszenia-Dąbrowska N, Zatonski W, García-Closas M. Genetic polymorphisms in base excision repair pathway genes and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006 Feb;15(2):353-8.
28. Newcomb P, **Egan KM**. Dairy foods and ovarian cancer. *Lancet*. 2006 Mar 11;367(9513):797-9.

29. **Egan KM**, Signorello L, Munro HM, Hargreaves MK, Hollis B, Blot WJ. Vitamin D insufficiency among African Americans in the Southern United States: Implications for cancer disparity. *Cancer Causes & Control* 2008 Jan 25; [Epub ahead of print]

C. RESEARCH SUPPORT

Ongoing Research Support

Gene Interactions, Estrogen, and Breast Cancer Risk

Role: PI Agency: NCI Type: R01 (CA105197) Period: 9/01/04-8/31/08

The aim of this project is to investigate the influence of polymorphisms in genes involved in estrogen synthesis and metabolism in the risk for breast cancer in a large, population-based case-control study.

Serum Vitamin D and Mortality from Eye Melanoma

Role: PI Agency: NCI Type: R03 (CA 119751) Period: 8/1/06-7/31/08

The objective of this study is to determine whether calcidiol (25(OH)D₃) in the serum and polymorphisms in the vitamin D receptor predict mortality in patients with melanoma of the eye.

Southeastern Regional Case-Control Study of Adult Glioma

Role: PI Agency: NCI Type: R01 (CA116174) Period: 12/1/06-11/30/11

The goal of this investigation is to establish a multi-center case-control study to explore dietary and genetic factors for adult-onset glioma.

Clinical Trial of Polyphenon in Prostate Cancer

Role: Co-I Agency: NCI Type: R01 (CA122060) Period: 7/1/07-6/30/12

The goal of this clinical trial is to assess rate of progression to prostate cancer at one year and safety in men treated with 400 mg EGCG provided by Polyphenon E per day following diagnosis of HGPIN (Principal Investigator: Nagi Kumar, PhD).

Melanoma SPORE Planning Grant

Role: Co-I Agency: Bankhead-Coley FL Biomedical Research Program Period: 7/1/07-6/30/10

The goal of this project is to lay groundwork for the eventual application for an NCI SPORE in cutaneous melanoma (Principal Investigator: Vern Sondak, MD).

Pending Projects

An in silico model for breast cancer risk prediction

Role: Co-I Agency: NCI Type: R21 Period: 12/1/08-11/30/10

The goal of this investigation is to examine genetic variation in the estrogen metabolic pathway in relation to breast cancer based on an in vitro modeling system (Principal Investigator: Fritz Parl, MD).

Lymphangiogenesis/Angiogenesis Gene Variants and Melanoma Outcome

Role: PI Agency: NCI Type: R01 Period: 12/1/08-11/30/13

The goal of this investigation is to examine genetic variation in the lymphangiogenesis/ angiogenesis pathways in relation to cutaneous melanoma survival in a historical cohort of patients undergoing wide excision biopsy for primary melanoma at the H. Lee Moffitt Cancer Center between 1986 and 2005.